OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B‐CELL LYMPHOMA TREATED WITH DOSE‐ADJUSTED EPOCH‐R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS
Lisa Roth(Cornell University), John P. Leonard(New York University), Catherine M. Bollard(Children's National), James Godfrey(City of Hope), Christopher J. Forlenza(Memorial Sloan Kettering Cancer Center), Melinda Pauly(Emory University), Matthew J. Barth(Roswell Park Comprehensive Cancer Center), Z. Chen(Cornell University), Deborah M. Stephens(University of North Carolina at Chapel Hill), Sarah Alexander(BC Children's Hospital), William Zeitler(University of Iowa Hospitals and Clinics), Tara J. O’Donohue, Matthew J. Oberley(Caris Life Sciences (United States)), Carla Casulo(University of Rochester Medical Center), Nancy L. Bartlett(Washington University in St. Louis), Zeinab Afify(Primary Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), William Martin‐Doyle(Brigham and Women's Hospital), Hema Dave(Children's National), Michael E. Williams(University of Virginia), Sheila Weitzman(Hospital for Sick Children), B. Appel(Hackensack University Medical Center), Jennifer Levine(Cornell University), Kimberly Davies(Boston Children's Hospital), Jakub Svoboda(UPMC Hillman Cancer Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k